You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR LOSMAPIMOD


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for Losmapimod

Trial ID Title Status Sponsor Phase Summary
NCT00633022 ↗ A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging Completed GlaxoSmithKline Phase 2 This study is being conducted to assess the potential anti-inflammatory effects of a 3-month treatment with GW856553, on the inflammatory activity within the aorta and carotid plaques, as assessed by FDG-PET/CT.
NCT01039961 ↗ PK Study of IV Formulation of GW856553 Completed GlaxoSmithKline Phase 1 The purpose of this study is to evaluate the safety of an IV infusion of GW856553 in healthy volunteers.
NCT01218126 ↗ Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstr Completed GlaxoSmithKline Phase 2 Randomised, double-blind, parallel-group, multi-centre study evaluating three doses of losmapimod (2.5mg, 7.5 mg and 15 mg) twice daily (BID) versus placebo on exercise tolerance. Eligible subjects will be randomised to treatment after a one-week run-in period. The duration of the treatment period is 24 weeks. An estimated 1000 subjects will be screened to reach the target enrolment of approximately 600 randomised subjects.
NCT01541852 ↗ Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen. Completed GlaxoSmithKline Phase 2 The main purpose of this study is to determine the effect of Losmapimod on blood vessels in patients with Chronic Obstructive Pulmonary Disease (COPD). Although COPD is a lung disease, it is also associated with an increased risk of cardiovascular disease (e.g. heart attacks and stroke). The investigators believe that this is a result of inflammation within the body, which damages the lining (endothelium) and walls of blood vessels. These changes can promote the development of fatty deposits within the walls of arteries (atherosclerosis) which can rupture and block arteries causing damage.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Losmapimod

Condition Name

Condition Name for
Intervention Trials
Facioscapulohumeral Muscular Dystrophy (FSHD) 3
Acute Coronary Syndrome 3
Pulmonary Disease, Chronic Obstructive 2
Atherosclerosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Muscular Dystrophy, Facioscapulohumeral 4
Muscular Dystrophies 4
Acute Coronary Syndrome 3
Pulmonary Disease, Chronic Obstructive 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Losmapimod

Trials by Country

Trials by Country for
Location Trials
United States 72
Germany 19
Canada 10
Chile 7
Argentina 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
California 6
Virginia 4
Missouri 4
Massachusetts 4
Florida 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Losmapimod

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 3
Phase 2 8
Phase 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 11
Enrolling by invitation 1
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Losmapimod

Sponsor Name

Sponsor Name for
Sponsor Trials
GlaxoSmithKline 9
Fulcrum Therapeutics 6
Royal Brompton & Harefield NHS Foundation Trust 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 15
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.